Wave Life Sciences, Inc.
WVE · XNASCIK 1631574fmd_0EJRXG2GMP4V4E1RYD50JA6QDVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 4 | 14 | 16 | 20 | 41 | 4 | 113 | 108 | 43 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Research and development | 41 | 79 | 134 | 175 | 131 | 122 | 116 | 130 | 160 | 183 |
| Total operating expenses | 57 | 106 | 174 | 224 | 173 | 168 | 166 | 181 | 219 | 258 |
| Operating income | (56) | (102) | (160) | (208) | (153) | (127) | (163) | (68) | (110) | (215) |
| Interest and investment income | – | – | – | – | 1 | 0 | 2 | 8 | 10 | 10 |
| Other non-operating income (expense) | 1 | 1 | 13 | 15 | 3 | 5 | 2 | 10 | 13 | 11 |
| Income before taxes | (55) | (101) | (147) | (194) | (151) | (122) | (161) | (58) | (97) | (204) |
| Income tax expense | 0 | 1 | 0 | 0 | (1) | (0) | 1 | (1) | 0 | 0 |
| Net income from continuing operations | (56) | (102) | (147) | (194) | (150) | (122) | (162) | (58) | (97) | (204) |
| Net income | (56) | (102) | (147) | (194) | (150) | (122) | (162) | (58) | (97) | (204) |
| Net income to common shareholders | (56) | (102) | (147) | (194) | (150) | (122) | (162) | (58) | (97) | (204) |